Opioid receptors in the gastrointestinal tract

Regulatory Peptides

Volumn 155, Issue 1-3, 2009, Pages 11-17

  Holzer, Peter ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Alvimopan; Constipation; Enteric nervous system; Methylnaltrexone; Naloxone; Opioid peptides; Opioid induced bowel dysfunction; Peripherally restricted opioid receptor antagonists; Prokinetic effects

Indexed keywords

17 METHYLNALTREXONE; ACETORPHAN; ALVIMOPAN; BETA ENDORPHIN; DELTA OPIATE RECEPTOR; DYNORPHIN; KAPPA OPIATE RECEPTOR; LAXATIVE; LEUCINE ENKEPHALIN; LOPERAMIDE; METENKEPHALIN; MORPHINE; MU OPIATE RECEPTOR; NALMEFENE; NALOXONE; NALTREXONE; OPIATE; OPIATE PEPTIDE; OPIATE RECEPTOR; OXYCODONE; PLACEBO;

ABDOMINAL DISCOMFORT; ANOREXIA; BLOOD BRAIN BARRIER; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG METABOLISM; FECES INCONTINENCE; GASTROINTESTINAL SECRETION; GASTROINTESTINAL TRACT; HUMAN; INTESTINE INNERVATION; INTESTINE PSEUDOOBSTRUCTION; IRRITABLE COLON; NAUSEA; PERISTALSIS; PRIORITY JOURNAL; REVIEW; STOMACH EMPTYING; VOMITING;

ANIMALS; CONSTIPATION; GASTROINTESTINAL TRACT; HUMANS; NALOXONE; NALTREXONE; NARCOTIC ANTAGONISTS; PIPERIDINES; QUATERNARY AMMONIUM COMPOUNDS; RECEPTORS, OPIOID;

EID: 67349119441     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2009.03.012     Document Type: Review

References (76)

1. Holzer P., and Lembeck F. Analgesia up to the twentieth century. In: Parnham M.J., and Bruinvels (Eds). Discoveries in Pharmacology. Psycho- and Neuro-pharmacology vol. 1 (1983), Elsevier, Amsterdam 357-377
2. Hamilton G.R., and Baskett T.F. In the arms of Morpheus: the development of morphine for postoperative pain relief. Can J Anaesth 47 (2000) 367-374
3. Lammers W.J., Lammers-van den Berg A.M., Morrison J.F., and Petroianu G.A. Translating Trendelenburg; back to the future. Naunyn Schmiedebergs Arch Pharmacol 373 (2006) 134-138
4. Trendelenburg P. Physiological and pharmacological investigations of small intestinal peristalsis. [Translation of the article "Physiologische und pharmakologische Versuche über die Dünndarmperistaltik"]. Arch Exp Pathol Pharmakol 81 (1917) 55-129
5. Trendelenburg P. Physiological and pharmacological investigations of small intestinal peristalsis. [Translation of the article "Physiologische und pharmakologische Versuche über die Dünndarmperistaltik"]. Naunyn-Schmiedeberg's Arch Pharmacol 373 (2006) 101-133
6. Schaumann O. Pain, the protective system and combinations with morphine-like effect. Wien Med Wschr 109 (1959) 78-81
7. Paton W.D.M. The action of morphine and related substances on contraction and on acetylcholine output of coaxially stimulated guinea-pig ileum. Br J Pharmacol 11 (1957) 119-127
8. Wood J.D., and Galligan J.J. Function of opioids in the enteric nervous system. Neurogastroenterol Motil 16 Suppl 2 (2004) 17-28
9. Snyder S.H. Opiate receptors in normal and drug-altered brain function. Nature 257 (1975) 185-189
10. Hughes J., Smith T.W., Kosterlitz H.W., Fothergill L.A., Morgan B.A., and Morris H.R. Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature 258 (1975) 577-580
11. Hughes J., Kosterlitz H.W., and Smith T.W. The distribution of methionine-enkephalin and leucine-enkephalin in the brain and peripheral tissues. Br J Pharmacol 61 (1977) 639-647
12. Kromer W. Endogenous and exogenous opioids in the control of gastrointestinal motility and secretion. Pharmacol Rev 40 (1988) 121-162
13. De Luca A., and Coupar I.M. Insights into opioid action in the intestinal tract. Pharmacol Ther 69 (1996) 103-115
14. Holzer P. Opioids and opioid receptors in the enteric nervous system: from a problem in opioid analgesia to a possible new prokinetic therapy in humans. Neurosci Lett 361 (2004) 92-95
15. Sanger G.J., and Tuladhar B.R. The role of endogenous opiates in the control of gastrointestinal motility: predictions from in vitro modelling. Neurogastroenterol Motil 16 Suppl 2 (2004) 38-45
16. Holzer P. Treatment of opioid-induced gut dysfunction. Expert Opin Investig Drugs 16 (2007) 181-194
17. Manara L., and Bianchetti A. The central and peripheral influences of opioids on gastrointestinal propulsion. Annu Rev Pharmacol Toxicol 25 (1985) 249-273
18. Holzer P., Schicho R., Holzer-Petsche U., and Lippe I.T. The gut as a neurological organ. Wien Klin Wochenschr 113 (2001) 647-660
19. Furness J.B. The enteric nervous system (2006), Blackwell, Oxford
20. Kurz A., and Sessler D.I. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 63 (2003) 649-671
21. Sternini C., Patierno S., Selmer I.S., and Kirchgessner A. The opioid system in the gastrointestinal tract. Neurogastroenterol Motil 16 Suppl 2 (2004) 3-16
22. Tonini M., Waterman S.A., Candura S.M., Coccini T., and Costa M. Sites of action of morphine on the ascending excitatory reflex in the guinea-pig small intestine. Neurosci Lett 144 (1992) 195-198
23. Waterman S.A., Costa M., and Tonini M. Modulation of peristalsis in the guinea-pig isolated small intestine by exogenous and endogenous opioids. Br J Pharmacol 106 (1992) 1004-1010
24. Lenard L., Halmai V., and Barthó L. Morphine contracts the guinea pig ileal circular muscle by interfering with a nitric oxide mediated tonic inhibition. Digestion 60 (1999) 562-566
25. Beubler E., and Lembeck F. Inhibition of stimulated fluid secretion in the rat small and large intestine by opiate agonists. Naunyn-Schmiedeberg's Arch Pharmacol 306 (1979) 113-118
26. Turnberg L.A. Antisecretory activity of opiates in vitro and in vivo in man. Scand J Gastroenterol 84 (1983) 79-83
27. Shahbazian A., Heinemann A., Schmidhammer H., Beubler E., Holzer-Petsche U., and Holzer P. Involvement of μ- and κ-, but not δ-, opioid receptors in the peristaltic motor depression caused by endogenous and exogenous opioids in the guinea-pig intestine. Br J Pharmacol 135 (2002) 741-750
28. Bianchi G., Ferretti P., Recchia M., Rocchetti M., Tavani A., and Manara L. Morphine tissue levels and reduction of gastrointestinal transit in rats. Correlation supports primary action site in the gut. Gastroenterology 85 (1983) 852-858
29. Camilleri M. Alvimopan, a selective peripherally acting μ-opioid antagonist. Neurogastroenterol Motil 17 (2004) 157-165
30. Holzer P. Methylnaltrexone for the management of unwanted peripheral opioid effects. Therapy 5 (2008) 531-543
31. Stacher G., Steinringer H., Schneider C., Vacariu-Granser G.V., Castiglione F., Gaupmann G., Weber U., and Stacher-Janotta G. Effects of the prodrug loperamide oxide, loperamide, and placebo on jejunal motor activity. Dig Dis Sci 37 (1992) 198-204
32. Matheson A.J., and Noble S. Racecadotril. Drugs 59 (2000) 829-835
33. Schwartz J.C. Racecadotril: a new approach to the treatment of diarrhoea. Int J Antimicrob Agents 14 (2000) 75-79
34. Salazar-Lindo E., Santisteban-Ponce J., Chea-Woo E., and Gutierrez M. Racecadotril in the treatment of acute watery diarrhea in children. New Engl J Med 343 (2000) 463-467
35. Prado D., and Global Adult Racecadotril Study Group. A multinational comparison of racecadotril and loperamide in the treatment of acute watery diarrhoea in adults. Scand J Gastroenterol 37 (2002) 656-661
36. Herndon C.M., Jackson K.C., and Hallin P.A. Management of opioid-induced gastrointestinal effects in patients receiving palliative care. Pharmacotherapy 22 (2002) 240-250
37. Liu M., and Wittbrodt E. Low-dose oral naloxone reverses opioid-induced constipation and analgesia. J Pain Symptom Manage 23 (2002) 48-53
38. DeHaven-Hudkins D.L., DeHaven R.N., Little P.J., and Techner L.M. The involvement of the μ-opioid receptor in gastrointestinal pathophysiology: therapeutic opportunities for antagonism at this receptor. Pharmacol Ther 117 (2008) 162-187
39. Reimer K., Hopp M., Zenz M., Maier C., Holzer P., Mikus G., Bosse B., Smith K., Buschmann-Kramm C., and Leyendecker P. Meeting the challenges of opioid-induced constipation in chronic pain management - a novel approach. Pharmacology 83 (2009) 10-17
40. Becker G., Galandi D., and Blum H.E. Peripherally acting opioid antagonists in the treatment of opiate-related constipation: a systematic review. J Pain Symptom Manage 34 (2007) 547-565
41. Greenwood-Van Meerveld B., Gardner C.J., Little P.J., Hicks G.A., and DeHaven-Hudkins D.L. Preclinical studies of opioids and opioid antagonists on gastrointestinal function. Neurogastroenterol Motil 16 Suppl 2 (2004) 46-53
42. Jurna I., Kaiser R., Kretz O., and Baldauf J. Oral naloxone reduces constipation but not antinociception from oral morphine in the rat. Neurosci Lett 142 (1992) 62-64
43. Simpkins J.W., Smulkowski M., Dixon R., and Tuttle R. Evidence for the delivery of narcotic antagonists to the colon as their glucuronide conjugates. J Pharmacol Exp Ther 244 (1988) 195-205
44. Reber P., Brenneisen R., Flogerzi B., Batista C., Netzer P., and Scheurer U. Effect of naloxone-3-glucuronide and N-methylnaloxone on the motility of the isolated rat colon after morphine. Dig Dis Sci 52 (2007) 502-507
45. Cheskin L.J., Chami T.N., Johnson R.E., and Jaffe J.H. Assessment of nalmefene glucuronide as a selective gut opioid antagonist. Drug Alcohol Depend 39 (1995) 151-154
46. Sykes N.P. An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliat Med 10 (1996) 135-144
47. Meissner W., Schmidt U., Hartmann M., Kath R., and Reinhart K. Oral naloxone reverses opioid-associated constipation. Pain 84 (2000) 105-109
48. Meissner W., Leyendecker P., Mueller-Lissner S., Nadstawek J., Hopp M., Ruckes C., Wirz S., Fleischer W., and Reimer K. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain 13 (2009) 56-64
49. Vondrackova D., Leyendecker P., Meissner W., Hopp M., Szombati I., Hermanns K., Ruckes C., Weber S., Grothe B., Fleischer W., and Reimer K. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J Pain 9 (2008) 1144-1154
50. Nadstawek J., Leyendecker P., Hopp M., Wirz S., Ruckes C., Fleischer W., and Reimer K. Patient assessment of a novel therapeutic approach for the treatment of severe, chronic pain. Int J Clin Pract 62 (2008) 1159-1167
51. Russell J., Bass P., Goldberg L.I., Schuster C.R., and Merz H. Antagonism of gut, but not central effects of morphine with quaternary narcotic antagonists. Eur J Pharmacol 78 (1982) 255-261
52. Neary P., and Delaney C.P. Alvimopan. Expert Opin Investig Drugs 14 (2005) 479-488
53. Yuan C.S., and Israel R.J. Methylnaltrexone, a novel peripheral opioid receptor antagonist for the treatment of opioid side effects. Expert Opin Investig Drugs 15 (2006) 541-552
54. Leslie J.B. Alvimopan: a peripherally acting μ-opioid receptor antagonist. Drugs Today (Barc) 43 (2007) 611-625
55. Reichle F.M., and Conzen P.F. Methylnaltrexone, a new peripheral μ-receptor antagonist for the prevention and treatment of opioid-induced extracerebral side effects. Curr Opin Investig Drugs 9 (2008) 90-100
56. Beattie D.T., Cheruvu M., Mai N., O'Keefe M., Johnson-Rabidoux S., Peterson C., Kaufman E., and Vickery R. The in vitro pharmacology of the peripherally restricted opioid receptor antagonists, alvimopan, ADL 08-0011 and methylnaltrexone. Naunyn-Schmiedeberg's Arch Pharmacol 375 (2007) 205-220
57. Kotake A.N., Kuwahara S.K., Burton E., McCoy C.E., and Goldberg L.I. Variations in demethylation of N-methylnaltrexone in mice, rats, dogs, and humans. Xenobiotica 19 (1989) 1247-1254
58. Yuan C.S., Doshan H., Charney M.R., O'Connor M., Karrison T., Maleckar S.A., Israel R.J., and Moss J. Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans. J Clin Pharmacol 45 (2005) 538-546
59. Rosow C.E., Gomery P., Chen T.Y., Stefanovich P., Stambler N., and Israel R. Reversal of opioid-induced bladder dysfunction by intravenous naloxone and methylnaltrexone. Clin Pharmacol Ther (2007) ;82:48-53
60. Yuan C.S., Foss J.F., O'Connor M., Osinski J., Karrison T., Moss J., and Roizen M.F. Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized, controlled trial. J Am Med Assoc 283 (2000) 367-372
61. Portenoy R.K., Thomas J., Moehl Boatwright M.L., Tran D., Galasso F.L., Stambler N., Von Gunten C.F., and Israel R.J. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study. J Pain Symptom Manage 35 (2008) 458-468
62. Thomas J., Karver S., Austin Cooney G., Chamberlain B.H., Watt C.K., Slatkin N.E., Stambler N., Kremer A.B., and Israel R.J. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 358 (2008) 2332-2343
63. Kraft M.D. Methylnaltrexone, a new peripherally acting μ-opioid receptor antagonist being evaluated for the treatment of postoperative ileus. Expert Opin Investig Drugs 17 (2008) 1365-1377
64. Fukuda H., Suenaga K., Tsuchida D., Mantyh C.R., Pappas T.N., Hicks G.A., DeHaven-Hudkins D.L., and Takahashi T. The selective μ opioid receptor antagonist, alvimopan, improves delayed GI transit of postoperative ileus in rats. Brain Res 1102 (2006) 63-70
65. Schmidt J., Stoffels B., Nazir A., Dehaven-Hudkins D.L., and Bauer A.J. Alvimopan and COX-2 inhibition reverse opioid and inflammatory components of postoperative ileus. Neurogastroenterol Motil 20 (2008) 689-699
66. Schmidt W.K. Alvimopan (ADL 8-2698) is a novel peripheral opioid antagonist. Am J Surg 182 (Suppl) (2001) 27S-38S
67. Paulson D.M., Kennedy D.T., Donovick R.A., Carpenter R.L., Cherubini M., Techner L., Du W., Ma Y., Schmidt W.K., Wallin B., and Jackson D. Alvimopan: an oral, peripherally acting, μ-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction - a 21-day treatment-randomized clinical trial. J Pain 6 (2005) 184-192
68. Webster L., Jansen J.P., Peppin J., Lasko B., Irving G., Morlion B., Snidow J., Pierce A., Mortensen E., Kleoudis C., and Carter E. Alvimopan, a peripherally acting μ-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain. Pain 137 (2008) 428-440
69. Delaney C.P., Wolff B.G., Viscusi E.R., Senagore A.J., Fort J.G., Du W., Techner L., and Wallin B. Alvimopan, for postoperative ileus following bowel resection: a pooled analysis of phase III studies. Ann Surg 245 (2007) 355-363
70. Tan E.K., Cornish J., Darzi A.W., and Tekkis P.P. Meta-analysis: alvimopan vs. placebo in the treatment of post-operative ileus. Aliment Pharmacol Ther 25 (2007) 47-57
71. Büchler M.W., Seiler C.M., Monson J.R., Flamant Y., Thompson-Fawcett M.W., Byrne M.M., Mortensen E.R., Altman J.F., and Williamson R. Clinical trial: alvimopan for the management of postoperative ileus after abdominal surgery: results of an international randomised, double-blind, multicentre, placebo-controlled clinical study. Aliment Pharmacol Ther 28 (2008) 312-325
72. Foss J.F., Fisher D.M., and Schmith V.D. Pharmacokinetics of alvimopan and its metabolite in healthy volunteers and patients in postoperative ileus trials. Clin Pharmacol Ther (2008) ;83:770-6
73. Gonenne J., Camilleri M., Ferber I., Burton D., Baxter K., Keyashian K., Foss J., Wallin B., Du W., and Zinsmeister A.R. Effect of alvimopan and codeine on gastrointestinal transit: a randomized controlled study. Clin Gastroenterol Hepatol 3 (2005) 784-791
74. Puig M.M., and Pol O. Peripheral effects of opioids in a model of chronic intestinal inflammation in mice. J Pharmacol Exp Ther 287 (1998) 1068-1075
75. Pol O., Alameda F., and Puig M.M. Inflammation enhances μ-opioid receptor transcription and expression in mice intestine. Mol Pharmacol 60 (2001) 894-899
76. Yoshida S., Ohta J., Yamasaki K., Kamei H., Harada Y., Yahara T., Kaibara A., Ozaki K., Tajiri T., and Shirouzu K. Effect of surgical stress on endogenous morphine and cytokine levels in the plasma after laparoscopoic or open cholecystectomy. Surg Endosc 14 (2000) 137-140